Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.
M. Talpaz
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Deciphera; Exelixis; Incyte; Merck; Millennium; Novartis; Takeda; Targeted Genetics
N. P. Shah
Research Funding - ARIAD
M. W. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Celgene; Genzyme
M. J. Mauro
Research Funding - ARIAD
I. W. Flinn
Research Funding - ARIAD
S. Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
W. Lindmark
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
J. M. Gozgit
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
T. Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
C. D. Turner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
F. G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
H. Kantarjian
Research Funding - ARIAD
J. E. Cortes
Consultant or Advisory Role - ARIAD; Novartis
Research Funding - Ambit BioSciences; ARIAD; Novartis